Literature DB >> 15741773

Optimum peripheral drug deposition in patients with cystic fibrosis.

P Brand1, T Meyer, S Häussermann, M Schulte, G Scheuch, T Bernhard, B Sommerauer, N Weber, M Griese.   

Abstract

In order to identify the optimum particle size and breathing pattern for high peripheral deposition of inhaled drugs in patients with cystic fibrosis, regional deposition in these patients was studied systematically as a function of particle size, inhalation volume and flow rate. Regional deposition was assessed using the single-breath regional deposition technique in which the concentration profile of inhaled and exhaled non-radioactive, monodisperse test particles is analyzed. Using this technique particle deposition within the functional dead space volume and peripherally can be assessed. Regional deposition was measured in 12 patients with cystic fibrosis using 2, 3, 4, and 5.5 microm particles, inhalation volumes of 500, 1000, 1500, and 2000 cm(3), and inhalation flow rates of 100, 250, 500, and 750 cm(3)/sec. Peripheral deposition was highest when 2-3-microm particles were inhaled with air-flow rates of 250-500 cm(3)/sec. With these parameters peripheral deposition increased with increasing inhalation volume and reached values of about 60% of the total drug inhaled. It has been shown that high peripheral drug deposition can be achieved in patients with CF when inhalations are performed using an optimized combination of particle size and breathing pattern.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741773     DOI: 10.1089/jam.2005.18.45

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  7 in total

1.  The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.

Authors:  David E Geller; Kenneth C Kesser
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

2.  Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model.

Authors:  Mayur K Ladumor; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2022-03-04       Impact factor: 3.579

Review 3.  Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis.

Authors:  R Siekmeier
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

4.  Controlled inhalation improves central and peripheral deposition in cystic fibrosis patients with moderate lung disease.

Authors:  Crystal Bourke; Sunalene Devadason; William Ditcham; Julie Depiazzi; Mark L Everard
Journal:  J Paediatr Child Health       Date:  2022-02-17       Impact factor: 1.929

5.  Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.

Authors:  Jonathan Plumb; Laura Robinson; Simon Lea; Antonia Banyard; John Blaikley; David Ray; Andrea Bizzi; Giorgina Volpi; Fabrizio Facchinetti; Dave Singh
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

6.  In vitro performance testing of the novel Medspray wet aerosol inhaler based on the principle of Rayleigh break-up.

Authors:  Anne H de Boer; Jeroen Wissink; Paul Hagedoorn; Iwan Heskamp; Wilbur de Kruijf; Ralf Bünder; Pieter Zanen; Paul Munnik; Cees van Rijn; Henderik W Frijlink
Journal:  Pharm Res       Date:  2007-12-08       Impact factor: 4.200

7.  Cell distribution and cytokine levels in induced sputum from healthy subjects and patients with asthma after using different nebulizer techniques.

Authors:  Sinem Koc-Günel; Ralf Schubert; Stefan Zielen; Martin Rosewich
Journal:  BMC Pulm Med       Date:  2018-07-13       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.